New drug combo hopes to tame tough breast cancer
NCT ID NCT04993430
First seen May 30, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new drug called HRS8807, alone or combined with another drug (SHR6390), in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to check safety and find the best dose for future studies. Participants must have already tried at least one hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS8807 (a drug) and SHR6390 (a drug)
What this could lead to
If successful, this could lead to a new treatment option for people with ER-positive, HER2-negative advanced breast cancer.
What could go wrong
This is a very early Phase 1 trial with only 46 participants. It is designed to find safe doses, not to prove the drug works. Many drugs fail in early testing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.